Article Text

Download PDFPDF

Immune evasion strategies of neuroendocrine-like Enzalutamide resistant prostate cancer
  1. Jennifer L Bishop1,2,
  2. Barinder Sangha2,3,
  3. Martin Gleave1,2 and
  4. Amina Zoubeidi1,2
  1. Aff1 grid.17091.3e0000000122889830Urologic SciencesUniversity of British Columbia Vancouver BC Canada
  2. Aff2 grid.412541.70000000106847796Vancouver Prostate Centre Vancouver BC Canada
  3. Aff3 grid.61971.380000000419367494Molecular Biology and BiochemistrySimon Fraser University Burnaby BC Canada

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

Treatment with Enzalutamide (ENZ) prolongs survival in patients with incurable castration-resistant prostate cancer (CRPC). However, the rapid recurrence of ENZ resistant tumors and the increased incidence of lethal neuroendocrine cancers in CRPC patients underscore the need for understanding how aggressive cell types emerge in resistant disease in order to design more effective therapies. As an unbiased approach to uncovering novel mechanisms of ENZ resistance, ENZ resistant cells were established from castration-resistant LNCaP xenografts that recurred under ENZ treatment in vivo and were genetically profiled using Illumina Platform gene expression analysis as well as RNA Seq. Genes involved in myeloid cell differentiation and immune checkpoint responses, as well as neuroendocrine differentiation, were strongly upregulated in ENZ resistant cell lines compared to CRPC controls. To investigate whether ENZ resistant cells may pass through a “dedifferentiated” state allowing progression to a neuroendocrine phenotype with immune-evasive properties, markers of cancer stem cells (CD133, CD44, CD117, CD49F, TROP2) neuroendocrine cells (neuron specific enolase, snaptophysin, chromagranin A, aurora kinase A, NCAM-1) and immune-evasion (programmed death ligands-1 and 2, B7H3, ICOSL) were assessed by quantitative PCR and flow cytometry. Indeed, all cancer stem cell markers were expressed at a higher frequency on ENZ resistant cells than CRPC controls and neuroendocrine markers were highly upregulated. Consistent with gene profiling results suggestive of a myeloid differentiation process, neuroendocrine-like resistant cells displayed an “immune” phenotype, expressing cell surface markers and transcription factors characteristic of dendritic cells (CD11c, HLA-DR, IRF8, ID2, AHR, BATF) that were absent from CRPC cells. Moreover, a greater frequency of neuroendocrine-like ENZ resistant cells expressed PD-L1, PD-L2 and ICOSL, and they showed intense staining for B7H3. Each of these molecules is well known to limit T cell effector responses and have been implicated in immune evasion strategies of solid tumors. Taken together, our results suggest that acquisition of resistance to Enzalutamide promotes the emergence of neuroendocrine-like cells that may be able to subvert anti-tumor T cell responses via dysregulation of antigen presentation or by enhancing immune checkpoint signaling. These results support anecdotal findings of increased frequency of neuroendocrine prostate cancer in patients undergoing long-term androgen withdrawal therapy and suggest investigating the utility of immunotherapies, such as anti-CTLA-4 or PD-1, in this subset of patients.